Uncategorized
Valeant, Croma reach agreement to expand U.S. Bausch + Lomb portfolio
An agreement between Valeant and Croma may provide additional ophthalmic opportunities for Bausch + Lomb’s United States market, according to a Bausch + Lomb press release.Valeant announced earlier this month that the company acquired hundreds of medical products including viscoelastics, IOLs, surgical instruments, dry eye and anti-inflammatory pharmaceuticals from Croma.